기업 정보 불러오는 중
Keep exploring
The themes Caris Life Sciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.US$47.6BA+
EXELExelixis, Inc.US$16.8BA+
JAZZJazz Pharmaceuticals plcUS$15.5BA
TECHBIO-Techne CorpUS$11.4BA+
HALOHalozyme Therapeutics, Inc.US$11.4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026년 10월 21일CBGraded C, now B
MCKMckesson Corporation2026년 11월 4일BAGraded B, now A
CVSCVS Health Corp2026년 11월 4일BAGraded B, now A
EWEdwards Lifesciences Corporation2026년 11월 4일BAGraded B, now A
GEHCGE Healthcare Technologies Inc.2026년 10월 28일CAGraded C, now A
어떻게 돈을 버는가
- Molecular profiling services97%
- Pharma research and development services4%
매출 비중은 six months ended June 30, 2026 기준 추정치이며, 제출된 보고서의 수치가 아닙니다.
경쟁 상대
- RHHBYFoundation Medicine (a Roche subsidiary)
- TEMTempus AIC
- 규모
- US$13.1B
- 이익률
- -12.5%
- GHGuardant HealthB
- 규모
- US$20.5B
- 이익률
- -37.9%
- NTRANateraB
- 규모
- US$46.3B
- 이익률
- -5.7%
- GRALGRAILD
- 규모
- US$5.2B
- 이익률
- -243.8%
- PSNLPersonalisD
- 규모
- US$1.7B
- 이익률
- -147.7%
무엇을 파는가6
MI Profile
A cancer tissue test that examines DNA, RNA, and selected proteins, then gives doctors a report about the tumor that can help guide treatment choices.
Caris Assure
A blood test that examines tumor-related DNA and RNA in the blood and compares them with blood-cell DNA to help distinguish cancer changes from age-related blood-cell changes.
Caris Detect
A blood test designed to look for signs of multiple cancers, including cancers that may not yet have been found through symptoms or other tests.
3개 더 보기
Caris ChromoSeq
A test of bone marrow or blood samples that examines DNA and RNA to help assess myeloid blood cancers, including acute myeloid leukemia and myelodysplastic syndromes.
Caris MI Clarity
A breast cancer test that examines digitized tissue-slide images and clinical information to estimate the chance of cancer returning at a distance from the original tumor.
FOLFIRSTai
A molecular signature included with certain cancer profiling results that helps doctors assess whether a patient with advanced colorectal cancer may benefit from particular chemotherapy combinations.
누가 사는가4
- Oncologists and other ordering physicians order tests for patients, often through hospitals, cancer centers, or medical groups.
- Government and commercial health insurers pay for some patient tests when they cover the test and its use.
- Biopharma companies pay for patient profiling, research support, and access to deidentified molecular and clinical data.
- Academic cancer centers and researchers use Caris data and collaborate on cancer research.
무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가
사업이 기대고 있는 것
- 1Most revenue comes from clinical molecular profiling, particularly tissue-based profiling.
- 2Clinical testing revenue depends on government and commercial insurers covering tests and setting reimbursement rates; Medicare-covered cases generated 40.0% (six months ended June 30, 2026, high) of molecular profiling services revenue.
- 3Laboratory work relies on sequencing equipment and supplies from third-party suppliers, including Illumina and Roche.
- 4The company depends on laboratory capacity, sample transport and handling, and computing systems to process patient samples and deliver results.
잘못될 수 있는 일
- 1A large share of current revenue comes from tissue-based profiling, so changes in test volumes or physician and patient adoption could affect the business.
- 2Insurers and government programs decide whether to cover tests and how much to reimburse; limited coverage or lower reimbursement could constrain testing and revenue.
- 3New and developing tests depend on validation, regulatory requirements, and payer decisions; delays or changes in these areas could prevent or limit their commercial use.
Caris Life Sciences, Inc. 소개
Caris analyzes DNA and RNA from cancer tissue and blood to find molecular features that may help doctors choose treatments. Its tests examine the whole exome—the protein-coding parts of DNA—or the whole transcriptome, and the company uses artificial intelligence (AI) and machine learning (ML) to interpret results. Caris also provides data and research services to drug companies and uses patient samples and data to investigate potential cancer drug targets.
- 본사
- Irving, Texas
- 설립
- 2008
- 상장 시장
- Nasdaq
- 회계연도 종료
- December 31
Caris Life Sciences, Inc.이(가) 미국 증권거래위원회(SEC)에 직접 제출한 공시로 만들었습니다. 수치는 보고된 그대로이며, 주당 이력은 오늘의 주식 수 기준으로 재계산했습니다. 이것은 사업을 설명하는 자료입니다. 투자 자문이 아니며 어떤 매수나 매도도 권유하지 않습니다.
